Categories: NewsPharmaceutical

CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

Provides funding of $952,000 to advance the Company’s revolutionary CytoR1 platform for the rapid sorting and recovery of live cells.

BLACKSBURG, Va., Feb. 09, 2023 (GLOBE NEWSWIRE) — CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced today that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant. Titled “Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring,” the grant will provide $952,558 in research funding to develop new features that will be embodied in the Company’s next generation CytoR2 Platform for advanced cell sorting.

The research will be conducted in the laboratories of Dr. Rafael Davalos, Virginia Tech’s L. Preston Wade Professor of Biomedical Engineering, Dr. Nathan Swami, UVA Professor of Electrical and Computer Engineering, and the CytoRecovery laboratory located at the Virginia Tech Corporate Research Center (VT CRC) in Blacksburg, VA, under the direction of Dr, Alex Hyler, who is the Principal Investigator (PI) for the NSF grant.

“We are pleased to receive this prestigious SBIR research grant from the NSF and for the validation of our technology that it represents,” stated Dr. Hyler. She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. To address this challenge, we have brought to market our CytoR1 Platform – a label-free, fully-integrated product system for cell sorting, enrichment, and recovery.”

The funding will be used to advance features, progress software, and develop new technologies for marker free cell sorting, including integrating the processes of cell sample preparation and expanding capabilities to monitor cells in the Company’s proprietary, microfluidic chips.

About CytoRecovery:
CytoRecovery has developed and markets the CytoR1 Platform, an integrated, benchtop cell sorting system that can enrich, sort, and recover live cell subpopulations from tissue and other sample types without the use of molecular markers. The Company’s proprietary technology uniquely enables the recovery of specific live cell subpopulations without altering the cells by exploiting biophysical differences in cell phenotypes. This label-free approach improves the quality of the cell samples recovered, providing more accurate representation of human disease, and enabling their maintenance and viability for further use in biomedical research procedures.

About the NSF: The U.S. National Science Foundation (NSF) is an independent federal agency that supports science and engineering in all 50 states and U.S. territories. NSF investments account for about 25% of federal support to America’s colleges and universities for basic research. NSF supports research partnerships between colleges and universities, industry, nonprofits, government and other organizations within the U.S. and across the globe.

For More Information:
https://www.cytorecovery.com                         
https://www.nsf.gov

CytoRecovery, Inc.
1872 Pratt Dr., #1350
Blacksburg, VA 24060
contactus@cytorecovery.com
Ph 540.961.7871 

CytoRecovery products are for research use only, not for use in medical or diagnostic procedures.

© CytoRecovery, Inc. 2023. All Rights Reserved

Staff

Recent Posts

Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for…

3 hours ago

Datasea Announces Closing of $2.25 Million Registered Direct Offering

BEIJING, July 3, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a…

3 hours ago

Medical College of Wisconsin Set to Lead Key Initiative as Part of EDA Tech Hub Phase 2 Funding

MILWAUKEE, July 3, 2024 /PRNewswire/ -- The U.S. Economic Development Administration (EDA) has awarded $49…

3 hours ago

StageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials under the Failure to File Cease Trade Order

TORONTO, ON / ACCESSWIRE / July 3, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTC PINK:SZLSF)…

3 hours ago

Optimind Pharma – Private Placement

Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind"…

4 hours ago

Veterinarians Moonlight as Bartenders for a Cause

VRCCO veterinarians serve beer at Ponch's Place for "Meet the Vet" nightsBEND, OR / ACCESSWIRE…

6 hours ago